Low Dose REN001 + High Dose REN001
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fatty Acid Oxidation Disorders
Conditions
Fatty Acid Oxidation Disorders
Trial Timeline
Apr 4, 2019 → Mar 21, 2022
NCT ID
NCT03833128About Low Dose REN001 + High Dose REN001
Low Dose REN001 + High Dose REN001 is a phase 1 stage product being developed by OnKure Therapeutics for Fatty Acid Oxidation Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT03833128. Target conditions include Fatty Acid Oxidation Disorders.
What happened to similar drugs?
6 of 12 similar drugs in Fatty Acid Oxidation Disorders were approved
Approved (6) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03833128 | Phase 1 | Completed |
Competing Products
20 competing products in Fatty Acid Oxidation Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 29 |
| GODEX + Placebo | Celltrion | Phase 3 | 47 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 35 |
| AZ compound | AstraZeneca | Phase 2 | 27 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 29 |
| metformin | Merck | Phase 2/3 | 34 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 35 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 29 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 35 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 27 |
| LJN452 | Novartis | Phase 1 | 29 |
| LCQ908 + placebo | Novartis | Phase 2 | 35 |
| Orlistat (Xenical) | Roche | Approved | 43 |
| Xenical, Pegasys, Copegus | Roche | Approved | 43 |
| Placebo + RO5093151 | Roche | Phase 1 | 29 |
| AMG 609 + Placebo | Amgen | Phase 1 | 29 |
| Glucagon | Novo Nordisk | Pre-clinical | 26 |
| Blood samples | Novo Nordisk | Pre-clinical | 18 |
| NNC0194-0499 + NNC0194-0499 + NC0194-0499 | Novo Nordisk | Phase 1 | 29 |